about
Scientific competency questions as the basis for semantically enriched open pharmacological space developmentOpen Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and BeyondAutomatic filtering and substantiation of drug safety signalsA chemocentric approach to the identification of cancer targetsPrediction of the P. falciparum target space relevant to malaria drug discoveryDrug-induced acute myocardial infarction: identifying 'prime suspects' from electronic healthcare records-based surveillance systemGathering and exploring scientific knowledge in pharmacovigilanceMechanisms of the Development of Allergy (MeDALL): Introducing novel concepts in allergy phenotypes.Paving the way of systems biology and precision medicine in allergic diseases: the MeDALL success story: Mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No: 261357; 2010-2015.Representativity of target families in the Protein Data Bank: impact for family-directed structure-based drug discovery.Chemical and biological profiling of an annotated compound library directed to the nuclear receptor family.Ligand-based approach to in silico pharmacology: nuclear receptor profiling.Connecting small molecules to nuclear receptor pathways.Coverage and bias in chemical library design.A chemogenomic approach to drug discovery: focus on cardiovascular diseases.The topology of drug-target interaction networks: implicit dependence on drug properties and target families.In silico directed chemical probing of the adenosine receptor family.iPHACE: integrative navigation in pharmacological space.Chemical probes for biological systems.Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.Indexing molecules with chemical graph identifiers.Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1New chromene scaffolds for adenosine A(2A) receptors: synthesis, pharmacology and structure-activity relationships.In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities.Exploring the effect of PARP-1 flexibility in docking studies.Distant polypharmacology among MLP chemical probes.Guided docking approaches to structure-based design and screening.Insights from Fragment Hit Binding Assays by Molecular Simulations.In silico pharmacology for drug discovery: applications to targets and beyondDrug repurposing: far beyond new targets for old drugs.In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling.Linking pharmacology to clinical reports: cyclobenzaprine and its possible association with serotonin syndromeA ligand-based approach to mining the chemogenomic space of drugs.Anticipating drug side effects by comparative pharmacology.MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine.PharmaTrek: A Semantic Web Explorer for Open Innovation in Multitarget Drug DiscoveryIdentification of Similar Binding Sites to Detect Distant Polypharmacology.Design of a general-purpose European compound screening library for EU-OPENSCREEN.Drug-Target Networks.In Silico Receptorome Screening of Antipsychotic Drugs.
P50
Q27144426-FE9B91C5-1A10-44A7-82B9-00BC975EB3CAQ27826351-26A6291F-5DFD-4AC7-B9A4-0A6ACBF7C07BQ28482131-0E4317D6-FA93-4B66-BB22-A7CB7F990BD8Q28482507-AD802C01-2F02-4CEF-98B6-18BB1B421DE9Q28534474-A2EE3820-3F6B-4E5D-AB02-C136A70A669EQ28535919-31F8D8E8-ECE7-4BF1-9DCF-1A329F412E30Q28536855-E2AB0016-8F49-4BE9-8EFB-1623DCD3D202Q30238498-C79D6781-C66B-4F82-A85C-239152C423F7Q30251797-B0BDE038-CC95-42A0-853B-AFF82B660517Q31027566-CE3A957A-0158-457C-AE04-946981D1C006Q33221735-760D89D3-1532-4661-AAAA-7FB154529668Q33264566-2B6FF329-4CFC-419F-BED4-901A80368B8BQ33300432-09EE39BA-FC21-445E-ABDE-B12037DA6DD6Q33329364-83F85114-324F-4A3A-A860-95168DFA0704Q33442689-E18B9378-684C-4B75-A71D-41CFA60A24CCQ33492392-9492A8B2-34B3-4B24-9AE7-2A7777AF170EQ33552006-49539DBE-89FC-4F5B-AE52-C321C5C316ABQ33751353-859E95B0-467B-4F73-8789-6A41C6AFACDEQ33752524-584DF8BA-B5B1-4197-90BB-4DBD8281F616Q33767343-66BB9516-CAAE-4D40-9B1A-ED277AA85DF9Q33925477-B3EE17BF-4465-45AD-88E1-35B526F4CD0CQ34132738-B75C2563-603E-401C-AAE8-E2E2CFB34215Q34296457-1A2D114A-1E2A-44A2-90FA-3D3D5C135358Q34466574-F9247C81-4225-41DE-9CA0-30C8C6B8B6EEQ34993719-928F86B9-5AEC-4D66-9D7A-1F8A17591776Q35388534-546F252F-1ED1-499E-BB1F-EB1DFA7774C5Q35699232-F2B8F4EC-8A2E-4CC8-8A51-29589D5252DEQ35777416-7EEF6877-EBF6-4D00-B099-A643C9856921Q35995265-43205160-A257-4660-92B3-A9786635607FQ36331528-3DC696E2-B77D-4432-8435-534E3622BFDEQ36840592-8D95D5E1-E5F5-4FB3-B62F-A4008A34D3C7Q37257186-F4D3C195-600F-4A06-A2A0-2278F0323FBAQ37270761-0A52100C-2759-4628-B3B9-195FF1DE84B8Q37775961-EBBF529F-E599-4310-B1DA-C2D3B9541BF9Q37831947-CDAB632F-B5A5-4AF7-8E62-C7CC9F962C7AQ38453607-36C14D3A-63D5-4779-B78A-16D9CFA6EBB5Q38915518-A9DC5829-C509-4712-BB8B-622E48E8DFB0Q39156659-1E02CBE4-8D00-42A9-890E-17527EA4D4D0Q39554596-D9DFCE9D-432D-4DE2-A14D-A72DB92709FFQ39554945-E99B7D3A-5FC4-4EF5-9A3D-68F9106A55F9
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jordi Mestres
@ast
Jordi Mestres
@en
Jordi Mestres
@es
Jordi Mestres
@nl
Jordi Mestres
@sl
type
label
Jordi Mestres
@ast
Jordi Mestres
@en
Jordi Mestres
@es
Jordi Mestres
@nl
Jordi Mestres
@sl
prefLabel
Jordi Mestres
@ast
Jordi Mestres
@en
Jordi Mestres
@es
Jordi Mestres
@nl
Jordi Mestres
@sl
P1053
B-3673-2009
P106
P21
P2456
P31
P3829
P496
0000-0002-5202-4501
P569
2000-01-01T00:00:00Z